Isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2) mutations are detected in approximately 12% of patients with MDS and are enriched in high-risk cases and severe neutropenia [79,80]. Here, IDH2 is linked to myelodysplastic syndrome.